Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …

Diffuse large B-cell lymphoma (DLBCL) is nowadays a curable disease with the frontline
treatment R-CHOP, but 30–40% of patients are still unresponsive or relapse thereafter. In …

Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …

Background Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60 …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

We report the results of GUIDANCE-01 (NCT04025593), a randomized, phase II trial of R-
CHOP alone or combined with targeted agents (R-CHOP-X) guided by genetic subtyping of …

The term diffuse large B‐cell lymphoma (DLBCL) includes a heterogeneous collection of
biologically distinct tumours. This heterogeneity currently presents a barrier to the successful …

Noninvasive disease monitoring and risk stratification by circulating tumor DNA (ctDNA)
profiling has become a potential novel strategy for patient management in B-cell lymphoma …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

Genetic classification helps to disclose molecular heterogeneity and therapeutic implications
in diffuse large B-cell lymphoma (DLBCL). Using whole exome/genome sequencing, RNA …